You are viewing an incomplete version of our website. Please click to reload the website as full version.

Browse our anti-Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) Antibodies

Full name:
anti-Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) Antibodies (CDKN2A)
On are 0 Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) Antibodies from different suppliers available. A total of 0 Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) products are currently listed.
ARF, ARF-INK4a, CDK4I, CDKN2, CMM2, INK4, INK4A, INK4a-ARF, Ink4a/Arf, MLM, MTS-1, MTS1, P14, P14ARF, P16, p16(INK4a), P16-INK4A, p16Cdkn2a, P16INK4, p16INK4a, P19, p19, P19ARF, Pctr1, TP16
list all antibodies Gene Name GeneID UniProt
Anti-Rat CDKN2A CDKN2A 25163 Q9R0Z3
Anti-Human CDKN2A CDKN2A 1029 P42771 , Q8N726
Anti-Mouse CDKN2A CDKN2A 12578 P51480 , Q64364

Show all synonyms

More Antibodies against Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) Interaction Partners

Human Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) interaction partners

  1. Data indicate that glioma tumor suppressor candidate region gene 2 product (GLTSCR2)-tumor suppressor protein (show TP53 Antibodies) p14ARF (ARF) binding was crucial for the nucleoplasmic translocation of ARF.

  2. data suggest that overexpression of p-RB1 (show RB1 Antibodies) in basal-parabasal layers of normal cervical epithelium was due to methylation/low functional-linked non-synonimous SNPs of P16 and RBSP3 (show CTDSPL Antibodies). This pattern was maintained during cervical carcinogenesis by additional deletion/mutation

  3. Our findings show that grade heterogeneity in urothelial carcinoma is characterized by increased MIB-1 labelling, and particularly in the FGFR3 (show FGFR3 Antibodies) mutant pathway, with homozygous deletions of CDKN2A in low- and high-grade areas

  4. Study shows exon 2 of CDKN2A was significantly methylated in tumors with significant correlations with cell proliferative activity suggesting that methylation changes in CDKN2A exon 2 are associated with breast carcinogenesis.

  5. Lipopolysaccharides-induced CDKN2A expression coincided with a 4.5-fold increase in ETS1 (ETS (show ETS1 Antibodies) proto-oncogene (show RAB1A Antibodies) 1) mRNA, suggesting that ETS1 (show ETS1 Antibodies) is involved in regulating CDKN2A This idea was confirmed by RNAi-mediated suppression or genetic deletion of ETS1 (show ETS1 Antibodies), which blocked CDKN2A expression and reduced cholangiocyte senescence.

  6. This study confirms the presence of CDKN2A and MC1R (show MSHR Antibodies) variants among Cypriot melanomas and supports existing evidence of a role for these variants in susceptibility to melanoma.

  7. The increased production of reactive oxygen species and the accumulation of lipid in cultured hepatic cells occurred when p16 expression was depleted with siRNA.

  8. Meta-analysis suggested that among high-grade osteosarcoma patients, the use of P16 protein expression as a noninvasive biomarker may be a potential predictor of the response to neoadjuvant chemotherapy in clinical application

  9. Prediction model based on the marker p16 determines progression risk in non-dysplastic Barrett's esophagus.

  10. Ectopic expression of the CDK (show CDK4 Antibodies) inhibitor p21(Cip1 (show CDKN1A Antibodies)) enhanced deregulated E2F (show E2F1 Antibodies) activity and pro-apoptotic E2F (show E2F1 Antibodies) target gene expression in cancer cells. Moreover, ectopic expression of p21(Cip1 (show CDKN1A Antibodies)) augmented cancer specific cytotoxicity of Ad-ARF-TK, and apoptosis induced by p21(Cip1 (show CDKN1A Antibodies)) was dependent on deregulated E2F (show E2F1 Antibodies) activity.

Mouse (Murine) Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) interaction partners

  1. p16 deficiency promotes nonalcoholic steatohepatitis via dysregulation of lipid metabolism and development of hepatic oxidative stress.

  2. Data show that the Wnt (show WNT2 Antibodies)-effector hepatocyte nuclear factor 1-alpha (Tcf1 (show HNF1A Antibodies)) is recruited to and triggers transcription of the Ink4/Arf tumor suppressor locus, such as as p15Ink4b (show CDKN2B Antibodies), p16Ink4a and p19Arf.

  3. deletion of the Cdkn2a gene in p53 (show TP53 Antibodies)(R172H) -induced SCCs promoted a dramatic increase in metastasis rates and a shorter survival in mice that developed these tumours, compared with those observed in mice with tumours in which Cdkn2a was deleted in the presence of a p53 (show TP53 Antibodies) loss-of-function mutation or wild-type p53 (show TP53 Antibodies).

  4. loss of Brca1 (show BRCA1 Antibodies), a tumor suppressor that functions in DNA damage repair, in the mammary epithelium induced senescence with induction of p16 and a decline of stem cell function, which was rescued by p16 loss.

  5. TWIST1 (show TWIST1 Antibodies)-E protein heterodimeric complexes may thus constitute the main active forms of TWIST1 (show TWIST1 Antibodies) with regard to senescence inhibition over the time course of breast tumorigenesis.

  6. AMPKalpha2 (show PRKAA2 Antibodies) isoform plays a fundamental role in anti-oxidant stress and anti-senescence

  7. that MEK (show MDK Antibodies) activity induced cell cycle arrest through accumulation of p16/19(cdkn2a)

  8. Data indicate the cyclin-dependent kinase inhibitor 2A (p19Arf) and interferon beta (IFN-beta (show IFNB1 Antibodies)) combination as a cancer immunotherapy strategy.

  9. Our findings reveal a novel role for p16(Ink4a) and cellular senescence in promoting insulin (show INS Antibodies) secretion by beta cells and in regulating normal functional tissue maturation with age.

  10. Loss of Nf2 (show NF2 Antibodies) and Cdkn2a/b have synergistic effects with PDGF-B (show PDGFB Antibodies) overexpression promoting meningioma malignant transformation.

Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) Antigen Profile

Antigen Summary

This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene\; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.

Alternative names and synonyms associated with Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A)

  • cyclin-dependent kinase inhibitor 2A (Cdkn2a) antibody
  • cyclin-dependent kinase inhibitor 2A (LOC100340625) antibody
  • cyclin-dependent kinase inhibitor 2A (CDKN2A) antibody
  • ARF antibody
  • ARF-INK4a antibody
  • CDK4I antibody
  • CDKN2 antibody
  • CMM2 antibody
  • INK4 antibody
  • INK4A antibody
  • INK4a-ARF antibody
  • Ink4a/Arf antibody
  • MLM antibody
  • MTS-1 antibody
  • MTS1 antibody
  • P14 antibody
  • P14ARF antibody
  • P16 antibody
  • p16(INK4a) antibody
  • P16-INK4A antibody
  • p16Cdkn2a antibody
  • P16INK4 antibody
  • p16INK4a antibody
  • P19 antibody
  • p19 antibody
  • P19ARF antibody
  • Pctr1 antibody
  • TP16 antibody

Protein level used designations for CDKN2A

CDK4I , Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4) , cell cycle inhibitor , cell cycle regulator , cyclin-dependent kinase 4 inhibitor A , cyclin-dependent kinase inhibitor 2a p16Ink4a , cyclin-dependent kinase inhibitor 2a p19Arf , p16-INK4 , p16-INK4a , CDK4 inhibitor p16-INK4 , cell cycle negative regulator beta , cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) , multiple tumor suppressor 1 , cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4) , cyclin-dependent kinase inhibitor 2A, isoforms 1/2 , cyclin-dependent kinase inhibitor protein , mitochondrial smARF

25163 Rattus norvegicus
100731972 Cavia porcellus
100340625 Oryctolagus cuniculus
1029 Homo sapiens
12578 Mus musculus
Did you look for something else?